Univariable and multivariable analysis of factors influencing 30-day mortality
| . | Univariable . | Multivariable . | ||||||
|---|---|---|---|---|---|---|---|---|
| P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | |||
| Lower . | Upper . | Lower . | Upper . | |||||
| Sex | ||||||||
| Female | — | — | — | — | ||||
| Male | .148 | 0.785 | 0.566 | 1.090 | ||||
| Age | <.001 | 1.059 | 1.044 | 1.075 | <.001 | 1.042 | 1.024 | 1.061 |
| Malignancy status at COVID-19 diagnosis | ||||||||
| Controlled disease | — | — | — | — | — | — | — | — |
| Stable disease | .183 | 1.364 | 0.863 | 2.157 | .767 | 1.081 | 0.647 | 1.806 |
| Active disease | <.001 | 2.494 | 1.718 | 3.619 | .001 | 1.981 | 1.305 | 3.008 |
| Baseline malignancy | ||||||||
| Aplastic anemia | — | — | — | — | ||||
| Lymphoid malignancies | .875 | 3032.714 | 0.000 | — | ||||
| Myeloid malignancies | .876 | 2974.523 | 0.000 | — | ||||
| Comorbidities | ||||||||
| 0-1 comorbidities | — | — | — | — | — | — | — | — |
| ≥2 comorbidities | <.001 | 2.802 | 2.019 | 3.889 | .027 | 1.503 | 1.050 | 2.229 |
| Type of last vaccination | ||||||||
| mRNA | — | — | — | — | ||||
| Vector-based | .359 | 0.740 | 0.389 | 1.409 | ||||
| Inactivated | .122 | 1.907 | 0.841 | 4.326 | ||||
| SARS-CoV-2 | ||||||||
| Omicron | — | — | — | — | ||||
| Alpha | .800 | 1.142 | 0.409 | 3.190 | ||||
| Beta | .960 | 0.000 | 0.000 | — | ||||
| Delta | .210 | 1.408 | 0.825 | 2.403 | ||||
| Wild type | .758 | 1.175 | 0.421 | 3.281 | ||||
| Not tested | .399 | 1.179 | 0.805 | 1.726 | ||||
| Vaccine doses before COVID-19 | ||||||||
| 1 dose | — | — | — | — | ||||
| 2 doses | .870 | 1.049 | 0.595 | 1.849 | ||||
| ≥3 doses | .637 | 0.866 | 0.478 | 1.572 | ||||
| Serological response before COVID-19 | ||||||||
| No response | — | — | — | — | ||||
| Weak response | .632 | 0.740 | 0.217 | 2.529 | ||||
| Optimal response | .124 | 0.425 | 0.143 | 1.264 | ||||
| COVID-19 treatment | ||||||||
| Corticosteroids | — | — | — | — | — | — | — | — |
| Antivirals + monoclonal antibodies | .001 | 0.333 | 0.171 | 0.651 | .010 | 0.407 | 0.206 | 0.803 |
| Antivirals | .010 | 0.570 | 0.372 | 0.874 | .099 | 0.680 | 0.431 | 1.075 |
| Monoclonal antibodies | <.001 | 0.123 | 0.061 | 0.247 | <.001 | 0.155 | 0.077 | 0.313 |
| Plasma | .852 | 1.077 | 0.493 | 2.355 | .243 | 1.605 | 0.726 | 3.549 |
| . | Univariable . | Multivariable . | ||||||
|---|---|---|---|---|---|---|---|---|
| P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | |||
| Lower . | Upper . | Lower . | Upper . | |||||
| Sex | ||||||||
| Female | — | — | — | — | ||||
| Male | .148 | 0.785 | 0.566 | 1.090 | ||||
| Age | <.001 | 1.059 | 1.044 | 1.075 | <.001 | 1.042 | 1.024 | 1.061 |
| Malignancy status at COVID-19 diagnosis | ||||||||
| Controlled disease | — | — | — | — | — | — | — | — |
| Stable disease | .183 | 1.364 | 0.863 | 2.157 | .767 | 1.081 | 0.647 | 1.806 |
| Active disease | <.001 | 2.494 | 1.718 | 3.619 | .001 | 1.981 | 1.305 | 3.008 |
| Baseline malignancy | ||||||||
| Aplastic anemia | — | — | — | — | ||||
| Lymphoid malignancies | .875 | 3032.714 | 0.000 | — | ||||
| Myeloid malignancies | .876 | 2974.523 | 0.000 | — | ||||
| Comorbidities | ||||||||
| 0-1 comorbidities | — | — | — | — | — | — | — | — |
| ≥2 comorbidities | <.001 | 2.802 | 2.019 | 3.889 | .027 | 1.503 | 1.050 | 2.229 |
| Type of last vaccination | ||||||||
| mRNA | — | — | — | — | ||||
| Vector-based | .359 | 0.740 | 0.389 | 1.409 | ||||
| Inactivated | .122 | 1.907 | 0.841 | 4.326 | ||||
| SARS-CoV-2 | ||||||||
| Omicron | — | — | — | — | ||||
| Alpha | .800 | 1.142 | 0.409 | 3.190 | ||||
| Beta | .960 | 0.000 | 0.000 | — | ||||
| Delta | .210 | 1.408 | 0.825 | 2.403 | ||||
| Wild type | .758 | 1.175 | 0.421 | 3.281 | ||||
| Not tested | .399 | 1.179 | 0.805 | 1.726 | ||||
| Vaccine doses before COVID-19 | ||||||||
| 1 dose | — | — | — | — | ||||
| 2 doses | .870 | 1.049 | 0.595 | 1.849 | ||||
| ≥3 doses | .637 | 0.866 | 0.478 | 1.572 | ||||
| Serological response before COVID-19 | ||||||||
| No response | — | — | — | — | ||||
| Weak response | .632 | 0.740 | 0.217 | 2.529 | ||||
| Optimal response | .124 | 0.425 | 0.143 | 1.264 | ||||
| COVID-19 treatment | ||||||||
| Corticosteroids | — | — | — | — | — | — | — | — |
| Antivirals + monoclonal antibodies | .001 | 0.333 | 0.171 | 0.651 | .010 | 0.407 | 0.206 | 0.803 |
| Antivirals | .010 | 0.570 | 0.372 | 0.874 | .099 | 0.680 | 0.431 | 1.075 |
| Monoclonal antibodies | <.001 | 0.123 | 0.061 | 0.247 | <.001 | 0.155 | 0.077 | 0.313 |
| Plasma | .852 | 1.077 | 0.493 | 2.355 | .243 | 1.605 | 0.726 | 3.549 |
CI, confidence interval; HR, Hazard ratio.